European Pharmaceutical Review

FEBRUARY 8, 2023

The number of blood cancer patients receiving CD19-directed CAR-T therapies is set to boom over the next decade from approximately 3,700 patients in 2021 to nearly 13,500 patients in 2031. This allows for a large total eligible patient population despite capturing less patient share relative to other CD19 CAR-T agents.

Marketing 95

Marketing Sales Physicians Patients 95

European Pharmaceutical Review

NOVEMBER 20, 2023

This will ensure that patients have rapid access to new treatment options and make us more independent from fragile supply chains,” commented Professor Dr Karl Lauterbach, Federal Minister of Health. But we will continue to improve the framework conditions for research and production.

Manufacturing 85

Manufacturing Medicine Biopharma Engineering 85

European Pharmaceutical Review

MAY 4, 2023

Data announced at the European Lung Cancer Congress (ELCC) earlier this month revealed the long-term efficacy and safety of RYBREVANT ® (amivantamab) in patients with post-platinum EGFR Ex20ins-mutated advanced non-small cell lung cancer (NSCLC). 3 , 4 There is a high unmet need for novel and targeted therapies for this patient population.

Food and Drug Administration 93

Food and Drug Administration Safety Medicine Patients 93

Impetus Digital

MARCH 15, 2024

In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). The field of oncology is rapidly growing and evolving.

Recruitment 78

Recruitment Healthcare Provider Patients Healthcare 78

European Pharmaceutical Review

JULY 18, 2022

Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States. Too few of these patients receive appropriate treatment. We are committed to facilitating access to treatment for even more patients in need,” commented Gabriel Baertschi, CEO of Grünenthal.

Medicine 83

Medicine Physicians Competition Patients 83

European Pharmaceutical Review

DECEMBER 2, 2022

The facility is planned for completion in 2027. We continue to invest in our global manufacturing infrastructure to bring much-needed medicines and vaccines to patients, around the world, and to deliver the next scientific breakthroughs.”. In 2021, the company invested €40 million in its Grange Castle facility. The post Pfizer’s €1.2

Manufacturing 95

Manufacturing Medicine Networking Medical 95

European Pharmaceutical Review

JUNE 15, 2023

Importantly, they identify potential sources of microbial contamination and assess their risk to patients. This microbial contamination can lead to a range of adverse events, such as infections, adverse reactions, or device failures, which can compromise patient safety and health outcomes. Sharma et al.

Manufacturing 82

Manufacturing Medical Safety Transportation 82

European Pharmaceutical Review

JANUARY 19, 2023

The contribution will enable the programme to reach additional physicians and medical students, further expanding the initiative that aims to extend the reach of clinical trials in underserved patient populations in US communities. The Winn Award Program has so far trained 114 early-stage investigator physicians.

Food and Drug Administration 83

Food and Drug Administration Physicians Medicine Food 83

European Pharmaceutical Review

JANUARY 10, 2023

Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. The drug can be used to treat a niche group of patients with high unmet need.

Food and Drug Administration 89

Food and Drug Administration FDA Food Medicine 89

Clarivate

APRIL 18, 2024

While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. More recent developments provide a look into Amazon’s interest in treating patients with chronic conditions, including a pharmacy consultation pilot for high-risk seniors with complex medical needs.

Retail 52

Retail Healthcare Healthcare Physicians 52

PM360

JULY 13, 2023

1 This increased technology spending has led to industry fragmentation, creating siloed data—which can leave providers with an incomplete picture of a patient’s health record—and an often-cumbersome experience for patients, leaving them to shoulder the burden of managing their own care. billion in 2020 and is expected to reach $381.7

Healthcare 98

Healthcare Healthcare Consulting Healthcare Provider 98

pharmaphorum

JANUARY 17, 2023

Preliminary results from a cohort of 101 patients in the study have suggested that they can detect longitudinal change in cognition in Alzheimer’s disease. It reckons the market opportunity for Winterlight’s technology could be worth around $30 million in 2027, and expects it to contribute around £2 million ($2.5

Healthcare 98

Healthcare Healthcare Marketing Patients 98

European Pharmaceutical Review

SEPTEMBER 28, 2023

EMA prepares for winter antibiotic shortages PFAS restriction in pharmaceutical manufacturing In its current form, the procedure currently underway could lead to a ban on all PFASs by 2027, with very limited derogations, EFPIA acknowledged. The organisation’s response included results from a patient impact analysis.

Pharmaceutical manufacturing 97

Pharmaceutical manufacturing Manufacturing Pharmaceutical Medicine 97

pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. Teplizumab is thought to work by preventing the activation of T cells that attack those cells.

FDA 52

FDA Patients Manufacturing Pharma 52

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. 1 We have been improving patient affordability for over a decade, across generic and brand medications, including specialty treatments—sometimes by more than 50%.

Prescription 52

Prescription Medical Distribution Patients 52

Medico Reach

SEPTEMBER 12, 2022

Upon immediately subjecting the patient to an X-ray, the barium appears white as doctors observe how it outlines the digestive tract. . Option to treat the patient during endoscopy. But since the patient is already sedated while performing the procedure, the doctor can treat the problem during endoscopy. billion by 2027.

Marketing 52

Marketing Doctors Training Medical 52

pharmaphorum

SEPTEMBER 23, 2022

In a statement , Ionis said that AZD8233 met its objectives in the phase 2b SOLANO trial in patients with hypercholesterolaemia, when given as a monthly 60mg dose, reducing LDL-C levels by 62% compared to placebo after 28 weeks, and thereby achieving the study’s primary endpoint. billion in sales by 2027, ahead of Repatha at $2.2

Sales 57

Sales Education Pharma Patients 57

pharmaphorum

JULY 18, 2022

If approved, atogepant is expected to be a strong competitor to Vydura, according to analysts at GlobalData, who point to strong clinical data in episodic and chronic migraine and the availability of three strengths that allows the dose to be more closely matched to a patient’s needs.

Sales 52

Sales Marketing Patients FDA 52

Medico Reach

DECEMBER 2, 2022

billion , and by 2027, it is expected to reach around an exciting amount of 115.1 from 2022 to 2027. Some clinical trials offered by PPD include: Early Development Consulting and Product Development PPD Biotech PPD FSP The site and patient-centered Solutions Clinical Development. billion with a CAGR of 11.0% Medpace Holdings.

Consulting 98

Consulting Specialization Medicine Medical 98

pharmaphorum

OCTOBER 1, 2022

The latest judgments relate to an attempt by Chinese drugmaker HEC Pharma to bring a generic version of fingolimod to market in the US, and Novartis defense of the 9,187, 405 patent which expires in December 2027.

Competition 52

Competition Pharma Marketing Sales 52

PM360

SEPTEMBER 21, 2023

This article covers some of the reasons these drugs were chosen, how the process for price negotiation will occur, and the impact for the industry and for patients. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

pharmaphorum

JANUARY 9, 2023

Albireo secured approval in the US and Europe for the ileal bile acid transport inhibitor (IBATi) drug in 2021 for the treatment of pruritus (itching) in patients with rare disorder progressive familial intrahepatic cholestasis (PFIC), and has said sales should reach $24 million this year.

Transportation 52

Transportation Sales Leads FDA 52

Pharmaceutical Technology

DECEMBER 16, 2022

GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively.

Marketing 59

Marketing Side effects Sales Safety 59

pharmaphorum

JULY 18, 2022

. “The acceptance of the filing of proposed biosimilar natalizumab by the European regulatory authorities means we are a critical step closer to getting this important medicine to the patients who need it the most,” said Polpharma Biologics’ chief executive Michael Soldan in a statement.

Competition 52

Competition Marketing Sales Medicine 52

PM360

OCTOBER 24, 2022

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. Social Responsibility.

Pharma 40

Pharma Education Medicine Manufacturing 40

Legacy MEDSearch

SEPTEMBER 20, 2022

The SavvyWire is the first and only Sensor-Guided TAVR solution, designed to support TAVR efficiency and lifetime patient management. The TAVR procedure was initially only indicated for inoperable patients with severe symptomatic aortic stenosis, and later for patients at high surgical risk. About OpSens Inc.

FDA 52

FDA Food and Drug Administration Recruitment Physicians 52

European Pharmaceutical Review

MARCH 4, 2024

percent through 2027. Therefore, biologics identification and characterisation poses unparalleled challenges, as does their manufacturing processes and routes of administration while maintaining patient safety and clinical efficacy. Standardising isolation, purification and storage processes are crucial areas for further improvement.

Food and Drug Administration 90

Food and Drug Administration Transportation FDA Medical 90

Medico Reach

SEPTEMBER 19, 2022

Remote monitoring and analysis of a patient’s health lower costs associated with the following aspects: Service costs Patient visit expenses Data storage costs Auxiliary insurance costs. Improved Patient Engagement. A satisfied patient is a vital asset for any healthcare provider. Enhanced Patient Outcomes.

Healthcare 52

Healthcare Healthcare Healthcare Provider Physicians 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. Impact Beyond Medicare The IRA won’t just impact negotiation with the government either. Reference: 1.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

pharmaphorum

JANUARY 27, 2023

An additional note of optimism is that UK biotechs achieved pivotal milestones in their development, with Verona Pharma reporting a successful phase 3 trial for Ensifentrine, the first novel compound in over 10 years to address the ongoing needs of more than 380 million patients worldwide suffering from Chronic Obstructive Pulmonary Disease (COPD).

Pharma 52

Pharma Manufacturing Biopharma Medicine 52

Medico Reach

FEBRUARY 8, 2023

Big data can help clinical trial design, allowing researchers to leverage genetic makeup, historical patient data, past trial results, demographics, and more to find the right participants. billion by 2027. R&D in Personalized Medicine Customized or precision medicine offers tremendous prospects for treating many illnesses.

Pharma 52

Pharma Medicine Marketing Prospecting 52

PM360

JUNE 29, 2022

But to succeed, players must deeply understand both the end-to-end consumer and patient experience and create an ecosystem of partners to deliver the care, products, and experiences that health-conscious consumers need. Prescription refills can now be placed with a simple click on a patient portal. Reconsider the Role of Packaging.

Retail 97

Retail Healthcare Healthcare Marketing 97

Legacy MEDSearch

JULY 24, 2023

Trial results are expected in 2027. SAINT therapy is the beginning of a revolution in psychiatry: fast, effective, and personalized treatments that give hope to patients who have failed to receive relief from traditional approaches,” said David Carreon, M.D.,

Medical 52

Medical Recruitment FDA Specialization 52

European Pharmaceutical Review

APRIL 14, 2023

billion by 2027… In five years and beyond… The event closed with further enthusiasm. It does take a community to move a drug into patients.” “There are challenges to overcome, but the depth of excitement around the field is such that the financing will come. That will solve problems and oligonucleotides will move forward.”

Manufacturing 88

Manufacturing Consulting Pharmaceutical Marketing 88

Legacy MEDSearch

MAY 23, 2022

Surgeons are tethered to the surgical tower by a power cable and by a light cord that is often implicated in OR fires and patient burns. BN by 2027. The expected benefits include ease of use, improved OR efficiency, reduction in costs, and better patient outcomes. But we are at the dawn of a new era.

Food and Drug Administration 52

Food and Drug Administration Medicine Recruitment Physicians 52

Pharmaceutical Technology

OCTOBER 13, 2022

Left to enter the bloodstream, these minute pieces of debris could travel to the brain and block blood vessels or arteries, resulting in a stroke for the patient. According to AorticLab, 190,000 patients worldwide underwent TAVI procedures in 2020 and, with an ageing population, it predicts that by 2027 there could be 390,000 cases.

Engineering 52

Engineering Doctors Medical Marketing 52